Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Akso Health Group is pitching an internet-healthcare pivot, but the latest filings show low-margin marketing-promotion revenue, nil interim medical-device revenue, a major impairment and a sharp cash shift into internet-hospital advances.
OpenBlockchAIn has a real 40 MW operating data center and an AI/HPC infrastructure pitch, but the latest filings show margin pressure, thin cash, heavy customer and energy-provider concentration, related-party control and non-binding pipeline claims.
OpenAEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenFirefly Neuroscience pairs an FDA-cleared Evoke EEG/ERP workflow, more than 85 active U.S. clinical sites and a 191,000-record brain-data set with a harder financial reality: Q1 2026 revenue was only $485,000, cash was $3.1 million before subsequent financings
OpenArgan finished fiscal 2026 with record backlog, no debt and nearly $895 million of cash and investments. The AGX question is whether Power-heavy backlog converts into profitable revenue without project execution pain.
OpenAENT is a profitable physical-media and collectibles distributor with more than $1 billion of annual revenue, improving margins, exclusive studio and label relationships, insider control and a balance sheet that depends on inventory, receivables and revolver a
OpenAdagio has pivotal VT data, FDA Breakthrough Device status, and a CE-Marked system, but no current revenue, a going-concern warning, and a cash runway that makes every regulatory milestone matter.
OpenAbbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.
Open